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INTRODUCTION
Malignant	transformation	of	a	mature	cystic	teratoma	is	an	
uncommon	complication	occurring	in	approximately	1-3%	
of	all	mature	cystic	teratomas	[1,2].	Although	any	of	the	con-
stituent	tissues	of	a	teratoma	has	the	potential	to	undergo	
malignant	transformation,	squamous	cell	carcinoma	(SCC)	is	
the	most	commonly	associated	cancer.	Other	tumors	arising	
in	a	mature	cystic	teratoma	include	adenocarcinoma,	thyroid	
carcinoma,	malignant	melanoma,	transitional	cell	carcinoma,	
sarcoma,	carcinoid	tumor,	and	neuroectodermal	tumor	[1,2].	
Malignant	change	is	rarely	recognized	preoperatively,	and	
no	specific	symptoms	exist	that	would	lead	one	to	suspect	
malignant	transformation	developing	from	a	mature	cystic	
teratoma.	Because	of	its	rarity,	few	reports	exist	of	preopera-
tive	diagnosis	of	this	tumor	by	magnetic	resonance	imaging	
(MRI),	in	particular	fat-suppressed	MRI.	We	report	MRI	findings	
from	a	very	rare	case	with	a	malignant	transformation	com-
prising	of	an	adenocarcinoma	in	a	mature	cystic	teratoma,	
classified	as	clinical	stage	IA,	and	we	briefly	review	the	litera-
ture	on	early	diagnosis.
CASE REPORT
A	79-year-old	multiparous	woman	(gravida	2,	para	2)	was	re-
ferred	to	our	hospital	from	a	local	hospital	with	a	pelvic	mass	
detected	by	ultrasonography.	In	the	initial	pelvic	examination,	
an	approximately	fist-sized,	hard,	solid	mass	was	detected	in	
the	pelvic	cavity.	Transvaginal	ultrasonography	revealed	a	
5×6	cm	sized	solid	mass	with	cystic	portions	on	the	left	ovary.	
The	tumor	marker	levels	was	as	follows;	carcinoembryonic	
antigen	(CEA),	134.7	ng/mL	(reference	range	<5.0	ng/mL);	CA-
125,	4.6	IU/mL	(reference	range	<25	IU/mL);	CA	19-9,	4.8	IU/
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The	most	common	form	of	malignant	transformation	developing	from	a	mature	cystic	teratoma	is	squamous	cell	carcinoma,	
representing	80%	of	malignant	transformations,	while	adenocarcinoma	accounts	for	approximately	5%.	Because	of	this	rarity,	
few	reports	exist	of	preoperative	diagnosis	of	this	tumor	by	magnetic	resonance	imaging,	in	particular	with	fat	suppression	
techniques.	Here,	we	report	magnetic	resonance	imaging	findings	and	clinical	features	of	a	79-year-old	woman	with	mucinous	
adenocarcinoma	arising	from	a	mature	cystic	teratoma	(measuring	5×6	cm),	classified	as	surgical	stage	IA.	Because	of	the	
poor	prognosis	of	malignant	transformation,	when	mature	cystic	teratomas	are	detected	(even	smaller	than	5	cm	tumor	size)	
in	postmenopausal	women,	serum	tumor	marker	carcinoembryonic	antigen	levels	and	fat-suppressed	magnetic	resonance	
imaging	may	be	potential	indicators	of	malignant	transformation.
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mL	(reference	range	<37.0	IU/mL).	Routine	laboratory	investi-
gations	revealed	no	abnormalities.	Pelvic	MRI	showed	a	6×6	cm	
sized	multiseptated	solid-cystic	mass	with	internal	calcification	
and	fatty	component	in	the	left	ovary	(Fig.	1A-C).	The	tumor	
had	an	obvious	solid	component	that	was	relatively	large	and	
tended	to	be	more	solid.	The	uterus	and	the	right	ovary	were	
unremarkable.	Gastroduodenoscopy	and	colonoscopy	were	
normal.	The	endometrial	biopsy	showed	negative	results.	
Exploratory	operation	was	planned	with	the	provisional	
diagnosis	of	a	malignant	transformation	of	a	mature	cystic	
teratoma,	based	on	the	age	of	patient,	high	level	of	serum	
CEA,	and	MRI	findings	of	a	large	solid	component.	In	the	lapa-
rotomy,	clear	yellowish	ascites	of	about	30	mL	were	found	
in	the	pelvic	cavity.	Cytologic	examination	of	the	ascites	was	
negative.	A	smooth-surfaced	spherical,	semisolid	cystic	tumor	
measuring	5×6×6	cm	was	found	to	originate	from	the	left	
ovary.	Neither	rupture	of	the	wall	nor	capsule	involvement	
was	observed.	The	uterus	and	right	ovary	were	macroscopi-
cally	normal.	The	left	ovarian	tumor	contained	mixed	yellow	
sebaceous	materials	with	hair	tufts,	and	a	solid,	but	necrotic,	
portion	measuring	3×4×3	cm	was	found	within	the	tumor.	
The	frozen	biopsy	in	the	operation	room,	which	is	a	routine	
procedure	for	ovarian	teratomas	in	our	hospital,	disclosed	an	
adenocarcinoma	combined	with	benign	cystic	teratoma.	A	
simple	total	hysterectomy,	bilateral	salpingo-oophorectomy,	
omentectomy,	and	pelvic	lymphadenectomy	were	performed.
The	pathologic	diagnosis	was	mucinous	adenocarcinoma	
arising	from	a	mature	cystic	teratoma	of	the	left	ovary.	The	
cystic	portion	of	the	ovary	consisted	of	well	differentiated	mu-
cinous	adenocarcinoma,	which	was	initially	associated	with	
dermoid	tissue	mature	cystic	teratoma	(Fig.	1C).	The	uterus	
and	right	ovary	were	normal,	and	metastases	to	the	omentum	
and	lymph	nodes	were	not	observed.	From	these	findings,	
the	case	was	classified	as	surgical	stage	IA.	One	month	after	
the	operation,	CEA	level	returned	to	normal	levels	(2.6	ng/mL).	
Her	postoperative	course	was	not	eventful.	
DISCUSSION
The	most	common	sign	of	mature	cystic	teratoma	with	
malignant	transformation	may	be	a	pelvic	mass	without	any	
Fig. 1. Mucinous adenocarcinoma arising 
from a mature cystic teratoma. Magnetic 
resonance imaging of the pelvis (A-C): 
Transaxial T1-weighted (A) and T2-weighted 
images (B), and transaxial T1-weighted 
image with fat-suppression (C) show a 6
×6 cm sized solid-cystic mass with fatty 
component (white arrows) in the left 
ovary. Underlying cyst wall is smooth, 
with no sign of transcapsular extension. 
Pathohistology (D): The cystic portion 
of the ovarian tumor consists of well 
differentiated mucinous adenocarcinoma, 
which is intimately associated with mature 
cystic teratoma (H&E, ×200).Adenocarcinoma arising from dermoid cyst
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specific	symptoms.	However,	some	clinical	features	of	this	
event	have	been	reported.	First,	this	tumor	is	age	related;	al-
though	the	ages	of	patients	with	this	tumor	ranged	from	21	
to	87	years	in	the	literature,	this	tumor	occurs	most	frequently	
in	postmenopausal	women	[3-5].	Second,	tumor	size	is	an	im-
portant	factor	contributing	to	a	differential	diagnosis	between	
a	malignant	and	mature	cystic	teratoma	[3-5].	In	report	by	
Kikkawa	et	al.	[3],	a	SCC	developing	from	a	mature	cystic	tera-
toma	was	significantly	larger	than	a	mature	cystic	teratoma,	
the	mean	size	of	37	squamous	cell	carcinomas	developing	
from	mature	cystic	teratomas	was	152.3	mm,	and	the	cutoff	
size	between	benign	and	malignant	tumors	was	99	mm.	On	
the	other	hand,	the	size	of	adenocarcinoma	tumors	varied	
from	the	smallest	tumor	size	of	4	mm	in	diameter	to	36	mm	[6].	
These	results	reveal	that	tumor	size	is	ineffective	in	contribut-
ing	to	the	preoperative	diagnosis	of	adenocarcinomas	arising	
from	mature	cystic	teratomas.
Measurement	of	serum	tumor	markers	and	imaging	are	two	
important	tools	in	the	differential	diagnosis	between	benign	
and	malignant	ovarian	tumors.	Our	patient	had	a	raised	pre-
operative	serum	CEA	level,	but	not	CA-125	and	SCC,	similar	
to	the	findings	in	the	previously	reported	case	[7].	CA	19-9	is	
known	to	be	a	good	marker	for	mature	cystic	teratomas,	and	
SCC	and	CEA	have	been	reported	as	more	useful	than	CA	19-9	
or	CA-125	in	the	diagnosis	of	malignant	transformation	of	
mature	cystic	teratoma.	CEA	may	be	the	most	useful	and	SCC	
was	second	in	determining	a	differential	diagnosis	between	a	
mature	cystic	teratoma	and	a	SCC	developing	from	a	mature	
cystic	teratoma	[3,7].	
The	mature	cystic	teratoma	is	a	tumor	that	can	be	easily	di-
agnosed	by	imaging	modalities	such	as	plain	radiography,	CT	
and	MRI	[4,8].	Most	mature	cystic	teratomas	show	radiolucent	
shadows	on	plain	radiography	and	significantly	low	density	
in	CT	because	fat	is	usually	contained	within	the	tumor.	With	
MRI,	mature	cystic	teratomas	are	seen	with	high	signal	inten-
sities	in	both	T1-weighed	and	T2-weighted	images,	and	the	
presence	of	fat	fluid	levels	or	chemical	shift	artifacts	are	also	
useful	findings	in	the	diagnosis	of	a	mature	cystic	teratoma	
(Fig.	1A,	B).	However,	few	reports	exist	regarding	diagnosis	of	
malignant	transformations	developing	from	a	mature	cystic	
teratoma	with	these	imaging	modalities.	Kido	et	al.	[2]	report-
ed	the	MRI	findings	for	six	mature	cystic	teratomas	with	ma-
lignant	transformations.	They	observed	solid	portions	in	five	
of	six	tumors	in	MRI,	and	solid	portions	in	two	tumors	were	
enhanced	by	gadolinium	to	varying	degrees	[2].	The	presence	
of	solid,	friable,	or	variegated	portions	within	the	mature	cystic	
teratoma	is	an	important	feature	in	the	diagnosis	of	malignant	
transformation,	and	this	tumor	generally	spreads	by	direct	in-
vasion	and	peritoneal	implantation	rather	than	by	metastasis	
to	the	regional	lymph	nodes.	In	the	present	case	(Fig.	1C),	the	
diagnosis	of	mature	cystic	teratoma	was	easily	made	through	
unique	MRI	findings	with	fat	suppression	techniques	arising	
from	the	fat	present	within	the	tumor.	The	usefulness	of	MRI	
with	fat	suppression	techniques	has	also	been	reported	in	
the	diagnosis	of	mature	cystic	teratomas	[9,10].	To	our	knowl-
edge,	no	other	reports	of	MRI	with	fat	suppression	techniques	
exist	in	the	diagnosis	of	malignant	transformation	developing	
from	a	mature	cystic	teratoma.	The	gross	appearance	of	ma-
ture	cystic	teratoma	with	malignant	transformation	has	been	
reported	to	resemble	that	of	cystic	teratomas	but	tends	to	be	
more	solid	[2,11].	The	present	case	also	had	an	obvious	solid	
component	and	was	relatively	large.
We	present	an	unusual	case	of	mucinous	adenocarcinoma	
arising	from	a	mature	cystic	teratoma	with	high	level	of	CEA	as	
the	only	clinical	evidence.	Fat	suppressed	MRI	may	be	helpful	
in	the	diagnosis	of	mature	cystic	teratomas	and	its’	malignant	
transformation	tend	to	have	a	relatively	larger	solid	compo-
nent.	Considering	that	malignant	transformation	is	usually	
observed	in	postmenopausal	women,	the	mere	presence	of	
a	relatively	large	solid	protuberance	in	such	a	patient	should	
raise	suspicions	that	malignant	transformation	may	have	oc-
curred.	Serum	tumor	marker	CEA	level	and	fat-suppressed	
MRI	may	be	helpful	in	evaluating	whether	mature	cystic	tera-
tomas,	even	smaller	than	tumor	size	<5	cm,	have	undergone	
malignant	transformation.
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